Dr Kenneth D’ Cruz joins Cytecare as Senior Consultant –Gastrointestinal and HBP Surgical Oncology

IMT News Desk
IMT News Desk
· 2 min read
Dr.Kenneth D’ Cruz, Senior Consultant -Gastrointestinal and HBP Surgical Oncology

The Cytecare Cancer Hospital, Bengaluru, pledge to create awareness about Cancer, recently announced the appointment of Dr Kenneth D’ Cruz as a Senior Consultant, Gastrointestinal and HBP Surgical Oncology. He has been in the field of surgical gastro-intestinal oncology for more than two decades, with a special focus on complex and advanced procedures in minimal access surgery, including laparoscopic gastrointestinal cancer surgery and major hepatobiliary procedures.

Dr. Cruz did his MBBS and M.S. from St. John’s Medical College , Bengaluru. Later, he pursued Specialisation in Bariatric Surgery, Surgical Gastroenterology and General Surgery. He served St. John’s Medical College and Hospital, Bengaluru as Professor of Surgery and Chief of Laparoscopic and Surgical Gastroenterology unit. His Areas of Expertise include- Laparoscopic and open gastrointestinal oncology surgery, including: Thoracoscopic Oesophageal resections, D2 Gastrectomy, Liver and Bile Duct Resections, Laparoscopy Pancreatic Surgery and Laparoscopic Colorectal Resections.

Dr. Kenneth D’Cruz in the past has worked with Mazumdar Shaw Multispecialty Hospital and Cancer Centre, Fortis Hospitals, Manipal Hospital and St. Philomena’s Hospital. He has also received Clinical Fellowship in Liver Transplantation and Hepatobiliary Surgery at National University Hospital, Singapore. He underwent training in Surgery of liver and Liver transplantation in London and Paris.

Commenting on the appointment, Suresh Ramu, CEO & Co Founder, Cytecare Hospitals, said “We are glad to have Dr. Kenneth D’Cruz as our Senior Consultant, Gastrointestinal and HBP Surgical Oncology. His experience will benefit our patients largely as he has a widespread experience in treating complicated cases with GI surgical diseases.  His joining the Cytecare team will definitely boost our efforts in dealing with rare and advanced GI cases.  His expertise in laparoscopic and open gastrointestinal oncology will definitely enhance the profile of Cytecare.’’

 

Read Next

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management
Corporate
January 27, 2026

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management

Company to launch product after the expiry of semaglutide patent in India Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to […]
Article by: IMT News Desk
Lupin receives highest ESG rating from CDP for climate change and water security
Corporate
January 27, 2026

Lupin receives highest ESG rating from CDP for climate change and water security

The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency at the highest level Lupin has received the highest ‘A’ leadership rating from Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency […]
Article by: IMT News Desk
AstraZeneca Pharma India receives CDSCO approval for breast cancer drug
Corporate
December 19, 2025

AstraZeneca Pharma India receives CDSCO approval for breast cancer drug

Dato-DXd is a specifically engineered antibody drug conjugate that targets TROP2, a protein frequently overexpressed in breast cancer AstraZeneca Pharma India announced that the Central Drugs Standard Control Organisation (CDSCO) has granted regulatory approval to import, sell, and distribute Datopotamab Deruxtecan (Dato-DXd) in India. The approval reflects AstraZeneca’s focus on bringing to life-changing medicines at […]
Article by: IMT News Desk
Novo Nordisk launches Ozempic in India
Corporate
December 12, 2025

Novo Nordisk launches Ozempic in India

Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living with uncontrolled type 2 diabetes mellitus Novo Nordisk announced the launch of Ozempic (injectable semaglutide) in India. Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living […]
Article by: IMT News Desk